The EMBO Journal · 2022 · 38 citations · 59 references
Life SciencesCell BiologyMolecular BiologyApoptosisDna RepairMolecular Cell BiologyDna DamageDna Damage SignalingDna Damage-induced ApoptosisDna Double-strand Break RepairDna Strand BreaksDouble-strand Break RepairDna Damage Checkpoint SignalingDna Damage Repair PathwaysDna Damage Response PathwaysDna Damage Response SignalingDna Damage ResponsesDna Double-strand Break Repair SignalingDouble-strand Break SignalingTumor Susceptibility Genes
In a genome-wide screening for components of the dsDNA-break-induced IKK-NF-κB pathway, we identified scores of regulators, including tumor susceptibility gene TSG101. TSG101 is essential for DNA damage-induced formation of cellular poly(ADP-ribose) (PAR). TSG101 binds to PARP1 and is required for PARP1 activation. This function of TSG101 is independent of its role in the ESCRT-I endosomal sorting complex. In the absence of TSG101, the PAR-dependent formation of a nuclear PARP1-IKKγ signalosome, which triggers IKK activation, is impaired. According to its requirement for PARP1 and NF-κB activation, TSG101-deficient cells are defective in DNA repair and apoptosis protection. Loss of TSG101 results in PARP1 trapping at damage sites and mimics the effect of pharmacological PARP inhibition. We also show that the loss of TSG101 in connection with inactivated tumor suppressors BRCA1/2 in breast cancer cells is lethal. Our results imply TSG101 as a therapeutic target to achieve synthetic lethality in cancer treatment.
59
Damian Szklarczyk, Annika L. Gable, David Lyon et al. · Nucleic Acids Research · 2018 · 19.2K citations · Full text
Genome engineering using the CRISPR-Cas9 system
F. Ann Ran, Patrick D. Hsu, Jason Wright et al. · Nature Protocols · 2013 · 11.7K citations · Full text
The Reactome pathway Knowledgebase
Antonio Fabregat, Konstantinos Sidiropoulos, Phani Garapati et al. · Nucleic Acids Research · 2015 · 6K citations · Full text
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · New England Journal of Medicine · 2009 · 3.6K citations · Full text
Medicine, Oncology, Pharmacology +17